JP2017529838A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529838A5 JP2017529838A5 JP2017512813A JP2017512813A JP2017529838A5 JP 2017529838 A5 JP2017529838 A5 JP 2017529838A5 JP 2017512813 A JP2017512813 A JP 2017512813A JP 2017512813 A JP2017512813 A JP 2017512813A JP 2017529838 A5 JP2017529838 A5 JP 2017529838A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 413
- 230000027455 binding Effects 0.000 claims description 119
- 239000012634 fragment Substances 0.000 claims description 119
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 80
- 239000000427 antigen Substances 0.000 claims description 57
- 102000036639 antigens Human genes 0.000 claims description 57
- 108091007433 antigens Proteins 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 22
- 210000004027 cell Anatomy 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 description 44
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 7
- 201000005787 hematologic cancer Diseases 0.000 description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 101100310663 Homo sapiens SP1 gene Proteins 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 102000052088 human IL3RA Human genes 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 208000017815 Dendritic cell tumor Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 101100288142 Mus musculus Klkb1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229960004931 histamine dihydrochloride Drugs 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046682P | 2014-09-05 | 2014-09-05 | |
| US62/046,682 | 2014-09-05 | ||
| PCT/US2015/048316 WO2016036937A1 (en) | 2014-09-05 | 2015-09-03 | Cd123 binding agents and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020199977A Division JP2021050216A (ja) | 2014-09-05 | 2020-12-02 | Ｃｄ１２３結合剤及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017529838A JP2017529838A (ja) | 2017-10-12 |
| JP2017529838A5 true JP2017529838A5 (enExample) | 2018-10-11 |
| JP6805130B2 JP6805130B2 (ja) | 2020-12-23 |
Family
ID=54150667
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512813A Active JP6805130B2 (ja) | 2014-09-05 | 2015-09-03 | Ｃｄ１２３結合剤及びその使用 |
| JP2020199977A Ceased JP2021050216A (ja) | 2014-09-05 | 2020-12-02 | Ｃｄ１２３結合剤及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020199977A Ceased JP2021050216A (ja) | 2014-09-05 | 2020-12-02 | Ｃｄ１２３結合剤及びその使用 |
Country Status (39)
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6040148B2 (ja) | 2010-04-20 | 2016-12-07 | ゲンマブ エー／エス | ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法 |
| EP3812398A3 (en) | 2015-01-23 | 2021-07-21 | Sanofi | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
| US10100118B2 (en) | 2015-04-08 | 2018-10-16 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD123 |
| MX383614B (es) | 2015-05-21 | 2025-03-14 | Harpoon Therapeutics Inc | Proteinas de union triespecificas y metodos de uso. |
| SMT202100092T1 (it) | 2015-06-29 | 2021-03-15 | Immunogen Inc | Anticorpi anti-cd123 e loro coniugati e derivati |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| JP6955507B2 (ja) | 2015-12-14 | 2021-10-27 | マクロジェニクス，インコーポレーテッド | Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法 |
| US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| AU2017267793B2 (en) * | 2016-05-20 | 2024-01-25 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| WO2017211731A1 (en) | 2016-06-06 | 2017-12-14 | F. Hoffmann-La Roche Ag | Fusion proteins for ophthalmology with increased eye retention |
| KR20190015520A (ko) | 2016-06-07 | 2019-02-13 | 마크로제닉스, 인크. | 조합 치료법 |
| TWI790206B (zh) * | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
| TWI781108B (zh) * | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| CN107840889A (zh) * | 2016-09-19 | 2018-03-27 | 上海吉倍生物技术有限公司 | 高亲和力的抗cd123抗体及其应用 |
| AU2017331256B2 (en) | 2016-09-21 | 2024-11-07 | Aptevo Research And Development Llc | CD123 binding proteins and related compositions and methods |
| US10844134B2 (en) | 2016-11-23 | 2020-11-24 | Harpoon Therapeutics, Inc. | PSMA targeting trispecific proteins and methods of use |
| KR102275008B1 (ko) | 2016-11-23 | 2021-07-13 | 하푼 테라퓨틱스, 인크. | 전립선 특이 막 항원 결합 단백질 |
| JP7685735B2 (ja) | 2016-12-02 | 2025-05-30 | アンヘレス セラピューティクス インコーポレイテッド | 合成免疫受容体およびその使用方法 |
| CA3049689A1 (en) * | 2017-02-06 | 2018-08-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for augmenting antibody mediated receptor signaling |
| JP7132232B2 (ja) | 2017-02-24 | 2022-09-06 | マクロジェニクス，インコーポレーテッド | Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用 |
| WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| ES3014984T3 (en) * | 2017-03-14 | 2025-04-28 | Sunshine Lake Pharma Co Ltd | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
| CA3063362A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
| AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| US11472880B2 (en) | 2017-08-14 | 2022-10-18 | Morphosys Ag | Humanized antibodies for CD3 |
| WO2019050521A1 (en) * | 2017-09-07 | 2019-03-14 | Macrogenics, Inc. | DOSAGE SCHEMES OF BISPECIFIC DIACORPS CD123 X CD3 IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| SI3694529T1 (sl) | 2017-10-13 | 2024-10-30 | Harpoon Therapeutics, Inc. | Trispecifične beljakovine in načini uporabe |
| MX2020004381A (es) * | 2017-10-27 | 2020-08-20 | Pfizer | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos. |
| JP2021505637A (ja) | 2017-12-12 | 2021-02-18 | マクロジェニクス，インコーポレーテッド | 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用 |
| SG11202007572VA (en) | 2018-02-15 | 2020-09-29 | Macrogenics Inc | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
| CN120399075A (zh) * | 2018-03-14 | 2025-08-01 | 诺维莫尼公司 | 抗-CD3ε抗体及其应用方法 |
| BR112020023330A2 (pt) | 2018-05-14 | 2021-04-20 | Harpoon Therapeutics, Inc. | porção de ligação para ativação condicional de moléculas de imunoglobulina |
| SG11202011306TA (en) | 2018-05-16 | 2020-12-30 | Janssen Biotech Inc | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy |
| MA52777A (fr) | 2018-05-24 | 2021-04-14 | Janssen Biotech Inc | Agents de liaison psma et utilisations correspondantes |
| CR20200564A (es) | 2018-05-24 | 2021-06-21 | Janssen Biotech Inc | Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos |
| JOP20190116A1 (ar) * | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| EP3856771A4 (en) | 2018-09-25 | 2022-06-29 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| US20220275081A1 (en) * | 2018-10-17 | 2022-09-01 | Good T Cells, Inc. | Binding molecule specific for lrig-1 protein and use thereof |
| TWI874341B (zh) | 2018-12-18 | 2025-03-01 | 美商健生生物科技公司 | 產生異二聚體抗體之方法 |
| CN113874400B (zh) * | 2019-03-11 | 2025-02-07 | 詹森生物科技公司 | 抗Vβ17/抗CD123双特异性抗体 |
| AR118720A1 (es) | 2019-04-19 | 2021-10-27 | Janssen Biotech Inc | Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3 |
| AU2020267504A1 (en) * | 2019-05-08 | 2021-12-02 | Janssen Biotech, Inc. | Materials and methods for modulating T cell mediated immunity |
| KR20220008866A (ko) | 2019-05-14 | 2022-01-21 | 하푼 테라퓨틱스, 인크. | EpCAM 결합 단백질 및 사용 방법 |
| CN118994397A (zh) | 2019-05-21 | 2024-11-22 | 诺华股份有限公司 | 针对bcma的三特异性结合分子及其用途 |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| CN113912694B (zh) * | 2019-07-24 | 2023-05-30 | 暨南大学 | 靶向cd133的结合蛋白和应用 |
| GB201912681D0 (en) | 2019-09-04 | 2019-10-16 | Eth Zuerich | Bispecific binding agent that binds to cd117/c-kit and cd3 |
| JP7745556B2 (ja) | 2020-02-21 | 2025-09-29 | マクロジェニクス，インコーポレーテッド | Ｃｄ１３７結合分子及びその使用 |
| CA3170833A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
| KR20230051617A (ko) | 2020-03-13 | 2023-04-18 | 얀센 바이오테크 인코포레이티드 | Siglec-3/cd33을 결합시키기 위한 물질 및 방법 |
| CN115666727A (zh) * | 2020-05-19 | 2023-01-31 | 詹森生物科技公司 | 包含t细胞重定向治疗剂和vla-4粘附途径抑制剂的组合物 |
| EP4153314A4 (en) | 2020-05-19 | 2024-05-22 | The Regents of The University of California | POLYPEPTIDES AND CONJUGATE VACCINES FOR INDUCING IMMUNE RESPONSES |
| AU2021339754A1 (en) | 2020-09-11 | 2023-05-25 | Janssen Biotech, Inc. | Methods and compositions for modulating beta chain mediated immunity |
| US12024559B2 (en) * | 2020-10-23 | 2024-07-02 | Asher Biotherapeutics, Inc. | Fusions with CD8 antigen binding molecules for modulating immune cell function |
| AU2021414400A1 (en) | 2020-12-31 | 2023-08-17 | Innate Pharma | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
| RS66868B1 (sr) | 2021-01-28 | 2025-06-30 | Regeneron Pharma | Kompozicije i postupci za lečenje sindroma oslobađanja citokina |
| CA3220458A1 (en) * | 2021-05-18 | 2022-11-24 | Janssen Biotech, Inc. | Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic |
| GB2638094B (en) | 2021-05-19 | 2026-03-04 | Asher Biotherapeutics Inc | IL-21 Polypeptides And Targeted Constructs |
| WO2023019121A2 (en) * | 2021-08-09 | 2023-02-16 | Merck Patent Gmbh | Proteins that decouple t cell-mediated tumor cytotoxicity from release of pro-inflammatory cytokines |
| WO2023138666A1 (en) * | 2022-01-19 | 2023-07-27 | Utc Therapeutics (Shanghai) Co., Ltd. | Circular rna and use thereof |
| CA3247475A1 (en) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR THE DESTRUCTION OF UNIVERSAL TUMOR CELLS |
| CN119365495A (zh) | 2022-05-27 | 2025-01-24 | 赛诺菲 | 与NKp46和BCMA变体结合的具有Fc工程化的自然杀伤（NK）细胞接合物 |
| JP2026506095A (ja) | 2023-02-17 | 2026-02-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｃｄ３／ｔａａ二重特異性抗体に応答する誘導ｎｋ細胞 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US6177078B1 (en) | 1995-12-29 | 2001-01-23 | Medvet Science Pty Limited | Monoclonal antibody antagonists to IL-3 |
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| EP1538206B1 (en) | 1997-09-16 | 2010-03-24 | Centocor, Inc. | Method for the complete chemical synthesis and assembly of genes and genomes |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2577082A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| CN101198698B (zh) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | 通过调节多肽缔合制备多肽的方法 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| JP2011507519A (ja) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法 |
| JP5694923B2 (ja) * | 2009-04-27 | 2015-04-01 | 協和発酵キリン株式会社 | 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体 |
| AU2010245011B2 (en) | 2009-04-27 | 2015-09-03 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| WO2011038301A2 (en) * | 2009-09-25 | 2011-03-31 | Xoma Technology Ltd. | Screening methods |
| JP6040148B2 (ja) | 2010-04-20 | 2016-12-07 | ゲンマブ エー／エス | ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法 |
| NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| PL2773671T3 (pl) | 2011-11-04 | 2022-01-24 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc |
| ES2924722T3 (es) * | 2012-05-18 | 2022-10-10 | Aptevo Res & Development Llc | Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3 |
-
2015
- 2015-09-03 DK DK15766973.0T patent/DK3189081T3/da active
- 2015-09-03 PE PE2017000397A patent/PE20171556A1/es unknown
- 2015-09-03 SI SI201531192T patent/SI3189081T1/sl unknown
- 2015-09-03 CN CN201580060369.4A patent/CN107074956B/zh active Active
- 2015-09-03 PL PL15766973T patent/PL3189081T3/pl unknown
- 2015-09-03 EA EA201790530A patent/EA037647B1/ru unknown
- 2015-09-03 CA CA2959171A patent/CA2959171C/en active Active
- 2015-09-03 US US14/844,194 patent/US9850310B2/en active Active
- 2015-09-03 WO PCT/US2015/048316 patent/WO2016036937A1/en not_active Ceased
- 2015-09-03 HU HUE15766973A patent/HUE048791T2/hu unknown
- 2015-09-03 CR CR20170079A patent/CR20170079A/es unknown
- 2015-09-03 AU AU2015311931A patent/AU2015311931B2/en not_active Ceased
- 2015-09-03 KR KR1020177008815A patent/KR102540192B1/ko active Active
- 2015-09-03 JP JP2017512813A patent/JP6805130B2/ja active Active
- 2015-09-03 MY MYPI2017700741A patent/MY186337A/en unknown
- 2015-09-03 MA MA053145A patent/MA53145A/fr unknown
- 2015-09-03 ES ES15766973T patent/ES2791249T3/es active Active
- 2015-09-03 EP EP20157898.6A patent/EP3722315A1/en not_active Withdrawn
- 2015-09-03 SM SM20200253T patent/SMT202000253T1/it unknown
- 2015-09-03 RS RS20200573A patent/RS60305B1/sr unknown
- 2015-09-03 ME MEP-2020-93A patent/ME03724B/me unknown
- 2015-09-03 MX MX2017002891A patent/MX384424B/es unknown
- 2015-09-03 MA MA40609A patent/MA40609B1/fr unknown
- 2015-09-03 EP EP15766973.0A patent/EP3189081B1/en active Active
- 2015-09-03 SG SG11201701599UA patent/SG11201701599UA/en unknown
- 2015-09-03 LT LTEP15766973.0T patent/LT3189081T/lt unknown
- 2015-09-03 HR HRP20200745TT patent/HRP20200745T1/hr unknown
- 2015-09-03 TW TW104129109A patent/TWI693233B/zh not_active IP Right Cessation
- 2015-09-03 JO JOP/2015/0216A patent/JO3568B1/ar active
- 2015-09-03 PT PT157669730T patent/PT3189081T/pt unknown
- 2015-09-03 UA UAA201703200A patent/UA120060C2/uk unknown
- 2015-09-04 AR ARP150102836A patent/AR101765A1/es unknown
- 2015-09-04 UY UY0001036289A patent/UY36289A/es not_active Application Discontinuation
-
2017
- 2017-02-26 IL IL250770A patent/IL250770B/en active IP Right Grant
- 2017-03-03 CL CL2017000515A patent/CL2017000515A1/es unknown
- 2017-03-03 NI NI201700025A patent/NI201700025A/es unknown
- 2017-03-06 CO CONC2017/0002196A patent/CO2017002196A2/es unknown
- 2017-03-13 PH PH12017500472A patent/PH12017500472A1/en unknown
- 2017-04-04 ZA ZA2017/02369A patent/ZA201702369B/en unknown
- 2017-04-05 EC ECIEPI201720812A patent/ECSP17020812A/es unknown
-
2020
- 2020-05-18 CY CY20201100453T patent/CY1122858T1/el unknown
- 2020-12-02 JP JP2020199977A patent/JP2021050216A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018534933A5 (enExample) | ||
| JP2021184721A5 (enExample) | ||
| JP2022526764A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2020516240A5 (enExample) | ||
| JP2021514664A5 (enExample) | ||
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| JP2020504723A5 (enExample) | ||
| JP2021510736A5 (enExample) | ||
| JP2022533418A5 (enExample) | ||
| JP2013527761A5 (enExample) | ||
| JP2017512765A5 (enExample) | ||
| JP2017526339A5 (enExample) | ||
| JP2018500014A5 (enExample) | ||
| JP2017534256A5 (enExample) | ||
| JP2020509027A5 (enExample) | ||
| RU2016144176A (ru) | Биспецифические антитела к her2 | |
| JP2015503909A5 (enExample) | ||
| JP2017510559A5 (enExample) | ||
| JP2014511179A5 (enExample) | ||
| JP2022533538A5 (enExample) | ||
| JP2012521218A5 (enExample) | ||
| JP2023549537A5 (enExample) | ||
| JP2013534515A5 (ja) | 受容体型チロシンキナーゼｃ−Ｍｅｔに対する抗体 | |
| JP2020522281A5 (enExample) |